See more : Fancamp Exploration Ltd. (FNCJF) Income Statement Analysis – Financial Results
Complete financial analysis of Mindset Pharma Inc. (MSSTF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Mindset Pharma Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Dubai Islamic Bank P.J.S.C. (DIB.AE) Income Statement Analysis – Financial Results
- Guangzhou Yuetai Group Co., Ltd. (600393.SS) Income Statement Analysis – Financial Results
- Natera, Inc. (NTRA) Income Statement Analysis – Financial Results
- Smartoptics Group AS (SMOPF) Income Statement Analysis – Financial Results
- Quest PharmaTech Inc. (QPTFF) Income Statement Analysis – Financial Results
Mindset Pharma Inc. (MSSTF)
About Mindset Pharma Inc.
Mindset Pharma Inc. develops and sells psychedelic medicines to treat neurological and psychiatric disorders in Canada. It focuses on developing MSP-1014, a psychedelic drug candidate. The company is based in Toronto, Canada.
| Metric | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|
| Revenue | 3.91M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 3.91M | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 100.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 7.39M | 2.22M | 0.00 | 0.00 |
| General & Administrative | 13.09M | 6.24M | 45.62K | 13.95K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 13.09M | 6.24M | 45.62K | 13.95K |
| Other Expenses | -33.41K | -71.37K | 0.00 | 0.00 |
| Operating Expenses | 20.48M | 8.46M | 45.62K | 13.95K |
| Cost & Expenses | 20.48M | 8.46M | 45.62K | 13.95K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 44.53K | 22.26K | 171.86K | 161.14K |
| EBITDA | -16.53M | -5.32M | -58.15K | -13.95K |
| EBITDA Ratio | -423.29% | 0.00% | 0.00% | 0.00% |
| Operating Income | -16.58M | -5.35M | -58.15K | -13.95K |
| Operating Income Ratio | -424.43% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -33.41K | -6.31M | 25.04K | 0.00 |
| Income Before Tax | -16.61M | -11.65M | -33.10K | -13.95K |
| Income Before Tax Ratio | -425.29% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 3.12M | 0.00 | 0.00 |
| Net Income | -16.61M | -11.65M | -33.10K | -13.95K |
| Net Income Ratio | -425.29% | 0.00% | 0.00% | 0.00% |
| EPS | -0.18 | -0.20 | 0.00 | 0.00 |
| EPS Diluted | -0.18 | -0.20 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 90.06M | 57.66M | 66.14M | 66.14M |
| Weighted Avg Shares Out (Dil) | 90.06M | 57.66M | 66.14M | 66.14M |
Mindset Pharma Announces Closing of Arrangement
Toronto, Ontario--(Newsfile Corp. - October 27, 2023) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company") is pleased to announce that further to its press releases of August 31, 2023, September 22, 2023 and October...
Mindset Pharma Announces Receipt of Final Order
Toronto, Ontario--(Newsfile Corp. - October 25, 2023) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company") is pleased to announce that further to its press releases of August 31, 2023, September 22, 2023, October 5,...
Mindset Pharma Announces Shareholder Approval of Arrangement
Toronto, Ontario--(Newsfile Corp. - October 19, 2023) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company") is pleased to announce that further to its press releases of August 31, 2023 and September 22, 2023, that...
Mindset Pharma Provides Clarifying Disclosure in Connection with Proposed Plan of Arrangement
Toronto, Ontario--(Newsfile Corp. - October 5, 2023) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company") wishes to clarify certain disclosure in its management information circular (the "Circular") dated September 19, 2023 for its special...
Mindset Pharma Announces Mailing of Circular and Receipt of Interim Order
Toronto, Ontario--(Newsfile Corp. - September 22, 2023) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company") announces that, further to its press release of August 31, 2023, its management information circular (the "Circular") and related...
Mindset Pharma to be acquired by Otsuka Pharmaceutical in all-cash deal
Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF) announced that it has agreed to be acquired by Otsuka Pharmaceutical Co, Ltd, through its wholly-owned Otsuka America Inc subsidiary, for about C$80 million in cash. The drug discovery and development company said each Mindset Pharma...
Otsuka Pharmaceutical to Acquire Mindset Pharma
Toronto, Ontario--(Newsfile Corp. - August 31, 2023) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset"), a drug discovery company developing novel, optimized, next-generation psychedelic and non-psychedelic medications to treat neuropsychiatric and neurological disorders with unmet medical needs,...
Mindset Pharma's Phase 2 psilocin prodrug study gets green light from UK regulators
Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF) has received approval from the UK Medicines and Healthcare products Regulatory Authority and the Research Ethics Committee to begin a Phase 2 study of its novel psilocin prodrug. The study will evaluate MSP-1014's safety and...
Mindset Pharma files two international patent applications under the Patent Cooperation Treaty
Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF) said it has filed two international patent applications under the Patent Cooperation Treaty (PCT) to protect its non-hallucinogenic novel non-tryptamine compounds, known as 'Family 6'. Mindset said the filings are based on pre-clinical studies and provide it...
Mindset Pharma CEO discusses expansion of drug discovery efforts into novel non-hallucinogenic therapeutics
Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF). is expanding its drug discovery efforts into novel non-hallucinogenic therapeutics in light of the success of its psychedelic therapeutic programs, the company's CEO James Lanthier highlighted in a letter to shareholders.
Source: https://incomestatements.info
Category: Stock Reports